Statins and chronic heart failure: Do we need a large-scale outcome trial?

Journal of the American College of Cardiology

Volumn 39, Issue 10, 2002, Pages 1567-1573

  Krum, Henry ^a,c   McMurray, John J ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CHOLESTEROL; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STATINE; UBIQUINONE;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM LESION; EVIDENCE BASED MEDICINE; HEART FAILURE; HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR DOWN REGULATION; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHRONIC DISEASE; HEART FAILURE, CONGESTIVE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; SURVIVAL RATE; UBIQUINONE;

EID: 0037094219     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)01827-2     Document Type: Review

References (56)

1. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and recurrent events trial investigators
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
4. Effect of metoprolol CR/XL in chronic heart failure: Meroprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
5. Effect of carvedilol on survival in severe chronic heart failure
6. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival study (ELITE II)
7. Baseline demographics of the Valsartan Heart Failure Trial: Val-HeFT Investigators
8. Candesartan in Heart failure-Assessment of reduction in Mortality and morbidity (CHARM): CHARM-Programme Investigators
9. Preliminary results of the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) study
10. Preliminary results of the Endothelin Antagonist Bosentan for Lowering Cardiac Events in heart failure (ENABLE) study
11. Coronary artery disease as the cause of incident heart failure in the population
12. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions
13. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease
14. Sudden death in heart failure: Vascular or electrical?
15. Acute coronary findings at autopsy in heart failure patients with sudden death: Results from the Assessment of Treatment with Lisinopril And Survival (ATLAS) trial
16. Dyslipidemias have a detrimental effect on left ventricular systolic function in patients with a first acute myocardial infarction
17. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris
18. From coronary artery disease to heart failure: Role of the hibernating myocardium
19. Simvastatin, an HMG-coenzyme a reductase inhibitor, improves endothelial function within 1 month
20. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
21. The effect of sarcolemmal cholesterol content on intracellular calcium ion concentration in cultured cardiomyocytes
22. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals
23. 1 receptor over-expression in hypercholesterolaemia
24. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure
25. Reduced dietary fat intake increases parasympathetic activity in healthy premenopausal women
26. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease
27. Statins: The effects on sympathetic nerve activity in heart failure
28. An overview of tumor necrosis factor alpha and the failing human heart
29. Inhibition of proinflammatory cytokine production by pravastatin
30. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro
31. Fluvastatin, a 3-hydroxy-3 methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction
32. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction
33. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis
34. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells
35. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor
36. Effects of HMG-CoA reductase inhibitors (statins) in patients with heart failure
37. Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients
38. Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH
39. Skin test anergy in advanced heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy
40. Serum total cholesterol, high density, lipoprotein and prognosis in patients with chronic heart failure
41. Low serum total cholesterol is associated with a marked increase in mortality in advanced heart failure
42. Does HDL-cholesterol level predict clinical outcome in advanced heart failure?
43. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors
44. Evidence of oxidative stress in chronic heart failure in humans
45. The effect of coenzyme Q10 in patients with congestive heart failure
46. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure
47. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure
48. Response of patients in classes III and IV of cardiomyopathy to therapy in blind and crossover trial with coenzyme Q10
49. Effect of coenzyme Q10 therapy in patients with congestive heart failure: A long-term multi-center randomized study
50. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy
51. Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: Antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy
52. The endotoxin-lipoprotein hypothesis
53. Plasma cytokine parameters and mortality in patients with chronic heart failure
54. Endotoxin and immune activation in chronic heart failure: A prospective cohort study
55. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure